Denali Therapeutics (DNLI) announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B agonist DNL343 in the treatment of amyotrophic ...
This milestone is a pivotal step in enabling the commencement of a Phase 2/3 clinical trial within the HEALEY ALS Platform Trial framework. The FDA has a period of 30 days to review the IND ...
Reducing the cost of research by 30%, decreasing trial time by 50%, and increasing patient participation by 67%, the HEALEY ALS Platform Trial is a vital step toward finding new ALS therapies. The ...
Hosted on MSN19d
Denali Therapeutics’ ALS therapy fails to meet primary endpoint in Phase II/III trialThe drug was investigated as part of the HEALEY ALS Platform trial. Its primary endpoints were to assess changes in disease severity over time using the ALS Functional Rating Scale-Revised ...
Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.
according to topline results from the Healey ALS platform trial. Fosigotifator did not demonstrate a significant effect on disease progression, combining function and mortality measures ...
Jan. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback